Prelude Therapeutics Inc (NAS:PRLD)
$ 3.6 -0.02 (-0.55%) Market Cap: 197.75 Mil Enterprise Value: 13.46 Mil PE Ratio: 0 PB Ratio: 0.94 GF Score: 38/100

Prelude Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 05:30PM GMT
Release Date Price: $6.4 (+3.90%)
Robert Burns
H.C. Wainwright & Co., LLC - Moderator

Thank you for joining our next fireside chat. I'm Robert Burns, Managing Director and Senior Biotech Analyst at H.C. Wainwright. I'm now joined by Kris Vaddi, the CEO of Prelude Therapeutics. Kris, thank you for being here today.

Kris Vaddi
Prelude Therapeutics Incorporated - CEO, Founder, Director

Thank you, thank you for the opportunity to join the conference.

Robert Burns
H.C. Wainwright & Co., LLC - Moderator

Always, always. So for those who may be unfamiliar with Prelude and its pipeline and story, why don't you provide some of the high-level overview as to Prelude as a company?

Kris Vaddi
Prelude Therapeutics Incorporated - CEO, Founder, Director

Absolutely, absolutely. So Prelude is a precision oncology company that really founded on the basis of discovering and developing very high quality small molecule therapeutics for patients who really need them. And over the past five to six years, we've really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot